Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Signaling Lymphocytic Activation Molecule (SLAM) family receptors (SLAMFs) are a group of nine type I transmembrane glycoproteins belonging to the immunoglobulin superfamily. They play critical roles in immune cell signaling, development, and function, regulating various aspects of immune responses including cytotoxicity, humoral immunity, cell adhesion, and cytokine production. Their function is largely controlled by interaction with intracellular adaptor proteins from the SAP family, leading to either activating or inhibitory signaling pathways. Due to their central role in immunity, SLAMFs are attractive therapeutic targets for modulating immune responses in autoimmunity or cancer.
Modulation of immune responses through agonism or antagonism of SLAMF receptors, influencing downstream signaling pathways via SAP family adaptors and Src-family kinases or SHP phosphatases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Signaling Lymphocytic Activation Molecule (SLAM) Family Receptors (SLAMFs).